Porownywarka

LL-37 vs KPV side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

LL-37KPV

Udostępnij porównanie peptydów

Wlasciwosc	LL-37	KPV
Kategoria	Odporność	Odporność
Znany tez jako	Cathelicidin, CAP18	Lys-Pro-Val, Alpha-MSH fragment
Zatwierdzony przez FDA	Nie	Nie
Status kliniczny	Investigational; source notes clinical trials for wound healing and FDA Category 2 restricted status due to limited safety data and immunogenicity concerns. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical research ongoing; no human clinical-trial benefit evidence was provided Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Antimicrobial, infections, biofilm disruption, wound healing	Gut inflammation, IBD, skin conditions and anti-inflammatory activity
Jak dziala	LL-37 is described as a positively charged, amphipathic host-defense peptide that can associate with negatively charged microbial membranes and disrupt them. Beyond direct antimicrobial effects, the source reports signaling roles that include neutralizing bacterial LPS, shaping inflammatory activity, recruiting immune cells to sites of injury or infection, and supporting epithelial repair. The source notes production in epithelial tissues such as skin, gut, and lung, as well as immune cells including neutrophils.	KPV is described as a short alpha-MSH-derived peptide with a proposed anti-inflammatory mechanism. In the supplied evidence, KPV uptake is linked to PepT1 transport, particularly in inflamed intestinal tissue. After cellular entry, laboratory findings associate KPV with dampened NF-kB activity and reduced production of inflammatory mediators such as TNF-alpha, IL-1beta and IL-6. The source also states that KPV does not appear to act through the classic melanocortin receptors used by alpha-MSH, so the mechanism remains a preclinical working model rather than a confirmed clinical pathway.
Typowe dawkowanie	100-200 mcg daily · Once daily	200-500 mcg daily · 1-2x daily
Dawkowanie z badań	100-200 mcg subcutaneous · Variable by protocol · Subcutaneous injection or topical	200-500 mcg daily · 4-8 weeks typical · Subcutaneous injection or oral capsules
Typowy czas trwania	Variable by protocol	4-8 weeks typical
Podanie	Subcutaneous injection or topical	Subcutaneous injection or oral capsules
Timing	Morning With or without food	Morning, or as directed in the source context With or without food
Poziom dowodów	Badania kliniczne	Przedkliniczne
Mozliwe skutki uboczne	Injection-site reactions (Reported as common in the source.) Skin toxicity (Source examples include ulcers and burning.) Allergic reactions (Reported by the source without severity grading.) +4 więcej Histamine release (Source flags caution for MCAS or histamine sensitivity.) Possible contribution to autoimmune conditions (Reported as a potential concern, not established causality.) High-dose toxicity concerns (Source flags concern at higher doses.) Limited long-term safety data (Source notes uncertainty around longer-term safety.)	Generally well tolerated (Reported by the source; human clinical safety evidence was not provided.) Injection-site reactions (Listed for injectable use.) Transient mild flu-like symptoms (Reported as mild and temporary in the source.) +4 więcej Mild gastrointestinal effects (Listed without additional severity detail.) Possible histamine release (Source advises caution for MCAS or histamine sensitivity; supporting human trial data was not provided.) Does not cause immunosuppression (Source reports this as a safety-related claim; corroborating clinical evidence was not supplied.) Cancer-history contraindication claim (Source lists this as a contraindication; independent clinical substantiation was not provided in the input.)
Podsumowanie researchu	The source presents LL-37 as a well-studied endogenous component of human innate immunity, with literature support for broad antimicrobial activity, membrane disruption, and distribution across epithelial and immune tissues. It also reports exploratory research on LL-37 or related mimics in laboratory anticancer models, Helicobacter pylori host-defense research, and ocular-surface pathogen contexts. The evidence described is strongest for LL-37 as a natural immune peptide; deliberate administration remains experimental in the supplied source, and the source flags that LL-37 may worsen inflammation in some disease settings.	The supplied research summary places KPV in a preclinical evidence tier. It cites Dalmasso and colleagues in Gastroenterology in 2008 for PepT1-dependent uptake and reduced intestinal inflammation in experimental colitis models, including DSS and TNBS mouse models, alongside lower pro-inflammatory cytokine signals. A 2016 PMC-listed study is described as showing fewer tumors in a mouse model of colitis-associated cancer when KPV activity depended on PepT1. The source emphasizes that these are animal and in vitro findings and does not provide published randomized human trials for inflammatory bowel disease, eczema or other promoted uses.
Referencje	Peptibase peptides Peptibase peptides +3 więcej Peptibase peptides Peptibase peptides Peptibase peptides	Źródło Źródło +1 więcej Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

LL-37

KPV

Kategoria

Odporność

Znany tez jako

Cathelicidin, CAP18

Lys-Pro-Val, Alpha-MSH fragment

Zatwierdzony przez FDA

Nie

Status kliniczny

Investigational; source notes clinical trials for wound healing and FDA Category 2 restricted status due to limited safety data and immunogenicity concerns.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical research ongoing; no human clinical-trial benefit evidence was provided

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Antimicrobial, infections, biofilm disruption, wound healing

Gut inflammation, IBD, skin conditions and anti-inflammatory activity

Jak dziala

LL-37 is described as a positively charged, amphipathic host-defense peptide that can associate with negatively charged microbial membranes and disrupt them. Beyond direct antimicrobial effects, the source reports signaling roles that include neutralizing bacterial LPS, shaping inflammatory activity, recruiting immune cells to sites of injury or infection, and supporting epithelial repair. The source notes production in epithelial tissues such as skin, gut, and lung, as well as immune cells including neutrophils.

KPV is described as a short alpha-MSH-derived peptide with a proposed anti-inflammatory mechanism. In the supplied evidence, KPV uptake is linked to PepT1 transport, particularly in inflamed intestinal tissue. After cellular entry, laboratory findings associate KPV with dampened NF-kB activity and reduced production of inflammatory mediators such as TNF-alpha, IL-1beta and IL-6. The source also states that KPV does not appear to act through the classic melanocortin receptors used by alpha-MSH, so the mechanism remains a preclinical working model rather than a confirmed clinical pathway.

Typowe dawkowanie

100-200 mcg daily · Once daily

200-500 mcg daily · 1-2x daily

Dawkowanie z badań

100-200 mcg subcutaneous · Variable by protocol · Subcutaneous injection or topical

200-500 mcg daily · 4-8 weeks typical · Subcutaneous injection or oral capsules

Typowy czas trwania

Variable by protocol

4-8 weeks typical

Podanie

Subcutaneous injection or topical

Subcutaneous injection or oral capsules

Timing

Morning

With or without food

Morning, or as directed in the source context

With or without food

Poziom dowodów

Badania kliniczne

Przedkliniczne

Mozliwe skutki uboczne

Injection-site reactions (Reported as common in the source.)
Skin toxicity (Source examples include ulcers and burning.)
Allergic reactions (Reported by the source without severity grading.)

+4 więcej

Histamine release (Source flags caution for MCAS or histamine sensitivity.)
Possible contribution to autoimmune conditions (Reported as a potential concern, not established causality.)
High-dose toxicity concerns (Source flags concern at higher doses.)
Limited long-term safety data (Source notes uncertainty around longer-term safety.)

Generally well tolerated (Reported by the source; human clinical safety evidence was not provided.)
Injection-site reactions (Listed for injectable use.)
Transient mild flu-like symptoms (Reported as mild and temporary in the source.)

+4 więcej

Mild gastrointestinal effects (Listed without additional severity detail.)
Possible histamine release (Source advises caution for MCAS or histamine sensitivity; supporting human trial data was not provided.)
Does not cause immunosuppression (Source reports this as a safety-related claim; corroborating clinical evidence was not supplied.)
Cancer-history contraindication claim (Source lists this as a contraindication; independent clinical substantiation was not provided in the input.)

Podsumowanie researchu

The source presents LL-37 as a well-studied endogenous component of human innate immunity, with literature support for broad antimicrobial activity, membrane disruption, and distribution across epithelial and immune tissues. It also reports exploratory research on LL-37 or related mimics in laboratory anticancer models, Helicobacter pylori host-defense research, and ocular-surface pathogen contexts. The evidence described is strongest for LL-37 as a natural immune peptide; deliberate administration remains experimental in the supplied source, and the source flags that LL-37 may worsen inflammation in some disease settings.

The supplied research summary places KPV in a preclinical evidence tier. It cites Dalmasso and colleagues in Gastroenterology in 2008 for PepT1-dependent uptake and reduced intestinal inflammation in experimental colitis models, including DSS and TNBS mouse models, alongside lower pro-inflammatory cytokine signals. A 2016 PMC-listed study is described as showing fewer tumors in a mouse model of colitis-associated cancer when KPV activity depended on PepT1. The source emphasizes that these are animal and in vitro findings and does not provide published randomized human trials for inflammatory bowel disease, eczema or other promoted uses.

Referencje

Peptibase peptides Peptibase peptides

+3 więcej

Peptibase peptides Peptibase peptides Peptibase peptides

Źródło Źródło

+1 więcej

Źródło

Pełny profil

Zobacz szczegóły